miR-4482 and miR-3912 aim for 3MODIFIER LETTER PRIMEUTR of ERG mRNA in prostate cancer

Ets-related gene (ERG) is overexpressed as a fusion protein in prostate cancer. During metastasis, the pathological role of ERG is associated with cell proliferation, invasion, and angiogenesis. Here, we hypothesized that miRNAs regulate ERG expression through its 3MODIFIER LETTER PRIMEUTR. Several bioinformatics tools were used to identify miRNAs and their binding sites on 3MODIFIER LETTER PRIMEUTR of ERG. The selected miRNAs expression was analyzed in prostate cancer samples by qPCR. The miRNAs overexpression was induced in prostate cancer cells (VCaP) to analyze ERG expression. Reporter gene assay was performed to evaluate the ERG activity in response to selected miRNAs. The expression of ERG downstream target genes was also investigated through qPCR after miRNAs overexpression. To observe the effects of selected miRNAs on cell proliferation and migration, scratch assay was performed to calculate the cell migration rate. miR-4482 and miR-3912 were selected from bioinformatics databases. miR-4482 and -3912 expression were decreased in prostate cancer samples, as compared to controls (p.05 and p.001), respectively. Overexpression of miR-4482 and miR-3912 significantly reduced ERG mRNA (p.001 and p.01), respectively) and protein (p.01) in prostate cancer cells. The transcriptional activity of ERG was significantly reduced (p.01) in response to miR-4482 and-3912. ERG angiogenic targets and cell migration rate was also reduced significantly (p.001) after miR-4482 and -3912 over-expression. This study indicates that miR-4482 and -3912 can suppress the ERG expression and its target genes, thereby, halt prostate cancer progression. These miRNAs may be employed as a potential therapeutic target for the miRNA-based therapy against prostate cancer.

Automated summary

This study found that miR-4482 and miR-3912 can suppress ERG expression and its downstream target genes, thereby halting the progression of prostate cancer. These miRNAs may be employed as a potential therapeutic target for miRNA-based therapy against prostate cancer.